Reports Q2 revenue $6,945 vs $39,847 last year. Cash and cash equivalents as of June 30, 2023, were approximately $0.6 million. Additional cash infusions subsequent to the close of the second quarter include net proceeds of approximately $1.8 million from the sale of assets related to the discontinued US Compounding operations and net proceeds of approximately $7.0 million from the Company’s equity financing transaction that occurred in August.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADMP:
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
- Adamis Pharmaceuticals prices 5.93M units at $1.35 in public offering
- Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
